The LoDoCo2 trial found a reduced cardiovascular risk with low-dose colchicine in patients with chronic coronary disease. In this substudy, attenuation of pericoronary adipose tissue did not differ ...
Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...
While conducting the CLEAR SYNERGY (OASIS 9) trial, lead author Sanjit Jolly, MD continued to treat some of his patients post–myocardial infarction (MI), including his late father, with colchicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results